27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
The US Food and Drug Administration (FDA) on Friday approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 28 September 2024
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
US pharma major Eli Lilly has announced executive leadership changes and the creation of neuroscience and immunology business units. Effective September 5, Lilly Bio-Medicines will split into two business units: Lilly Neuroscience and Lilly Immunology. 18 August 2021
Californian immunotherapy company Gritstone Bio has received an investment of up to $20.6 million to take forward its next-generation coronavirus vaccine. 17 August 2021
The Russian government may expand the list of purchased high-priced drugs for its needs by beginning purchases of risdiplam – a drug for treatment of spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent 17 August 2021
The China National Medical Products Administration (NMPA) has further approved Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in pediatric patients. 17 August 2021
US privately-held biotech HiberCell today announced the acquisition of Genuity Science, a life science technology company – previously known as WuXi NextCODE and with Chinese backing - that provides world-leading genomics and multi-omic analytics bolstered by an advanced artificial intelligence (AI) and machine learning (ML) platform to illuminate the underlying cause of cancer and other diseases. 17 August 2021
German biopharma CureVac offered a couple of updates on its partnered programs as it presented its quarterly financial results on Monday. 17 August 2021
US biotech giant Amgen has survived periods of accelerated erosion of legacy products before, but investors may not be aware of the erosion risk facing the company in 2025-2030, commented SVB Leerink Research analyst Geoffrey Porges. 17 August 2021
US biopharma Travere Therapeutics has announced positive top-line interim results from the ongoing pivotal Phase III PROTECT study of sparsentan, an investigational product candidate for the treatment of IgA nephropathy (IgAN). 17 August 2021
US biotech Incyte and China’s InnoCare have announced that Incyte and a subsidiary of InnoCare have entered into a collaboration and license agreement for the development and commercialization of tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in Greater China. 17 August 2021
Japan’s largest drugmaker Takeda is currently developing multiple microbiome-targeting agents through a number of collaborations with innovative small companies. 17 August 2021
The government of Russia’s capital Moscow city, together with private investors will invest about 10 billion roubles ($137 million) in the construction of at least three large-scale pharmaceutical enterprises. 17 August 2021
Shares in British biotech Tiziana Life Sciences rose nearly 4% on Tuesday morning, after the firm announced positive results for its nasally-administered COVID-19 therapy foralumab. 17 August 2021
US biotech companies Exelixis and Invenra have expanded their discovery and licensing collaboration to include an additional 20 oncology targets. 16 August 2021
For many years, artificial intelligence (AI), in particular machine learning, have been touted as potentially transformational technologies for drug discovery and development. 16 August 2021
The US Food and Drug Administration (FDA) has amended the emergency use authorizations (EUAs) for certain COVID-19 vaccines to allow for the use of an additional in some immuno-compromised people. 16 August 2021
China’s Brii Biosciences has announced that the Phase III portion of the ACTIV-2 study evaluating its monoclonal neutralizing antibody combination therapy, BRII-196/BRII-198 has completed enrollment of 846 participants, in sites in the USA, Brazil, South Africa, Mexico and Argentina. 16 August 2021
Tokyo-based drugmaker Eisai has announced the Japanese launch of Tazverik Tablets 200mg (tazemetostat hydrobromide) for relapsed or refractory EZH2 gene mutation-positive follicular lymphoma, when standard treatment is not applicable. 16 August 2021
Lebrikizumab led to significant improvements with at least 75% skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in ADvocate 1 and ADvocate 2 Phase III clinical trials announced today. 16 August 2021
Shares of USA-based oncology specialist Sesen Bio were all but annihilated on Friday, after the company revealed a major setback for its lead drug candidate, with the stock falling 57% by close of trading and a further 17.5% to $1.74 in after-hours trading. 16 August 2021
The US Food and Drug Administration has granted approval for Ticovac (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. 16 August 2021